sourcing the best research evidence in ophthalmology
January 1, 2017
Clinical Trial
Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
Holland EJ, Luchs J, Karpecki PM, Nichols KK, Jackson MA, Sall K, Tauber J, Roy M, Raychaudhuri A, Shojaei A.
Ophthalmology. 2017 Jan;124(1):53-60. Full text | Metrics.
Main finding: Lifitegrast ophthalmic solution 5.0% significantly reduced signs and improved symptoms of eye dryness compared with placebo.
Participants: ≥18 years, established history of bilateral Dry Eye Disease
Intervention:
Group 1: Lifitegrast 5.0% bd for 84 days Group 2: placebo
OPUS-2
December 1, 2015
Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
Tauber J, Karpecki P, Latkany R, Luchs J, Martel J, Sall K, Raychaudhuri A, Smith V, Semba CP.
Ophthalmology. 2015 Dec;122(12):2423-31. Full text | Metrics.
February 1, 2014
Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
Sheppard JD, Torkildsen GL, Lonsdale JD, D’Ambrosio FA Jr, McLaurin EB, Eiferman RA, Kennedy KS, Semba CP.
Ophthalmology. 2014 Feb;121(2):475-83. Full text | Metrics.
OPUS-1
Share This Article :
Source Archive